Details of the Drug

General Information of Drug (ID: DMB1N6P)

Drug Name
Impoyz
Synonyms
Clobetasol propionate; CLOBETASOL PROPIONATE; 25122-46-7; Clobetasol 17-propionate; Clobex; Temovate; Dermovate; Embeline; Embeline E; Clobesol; Cormax; Olux; Temovate E; Olux-E; clobetasol 17-propanoate; GR 2/925; C25H32ClFO5; MLS000028708; Clobestasol propionate; Clobetasol propionate [USAN:JAN]; CGP 9555; CCI 4725; EINECS 246-634-3; 21-Chloro-9-fluoro-11beta,17-dihydroxy-16beta-methylpregna-1,4-diene-3,20-dione 17-propionate; UNII-779619577M; [(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12
Indication
Disease Entry ICD 11 Status REF
Scalp dermatosis N.A. Approved [1]
Plaque psoriasis EA90.0 Phase 2 [2]
Affected Organisms
Humans and other mammals
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 467
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 59 +/- 36 ng/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 5 h [3]
Metabolism
The drug is metabolized via the liver [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.10926 micromolar/kg/day [5]
Chemical Identifiers
Formula
C25H32ClFO5
IUPAC Name
[(8S,9R,10S,11S,13S,14S,16S,17R)-17-(2-chloroacetyl)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate
Canonical SMILES
CCC(=O)O[C@@]1([C@H](C[C@@H]2[C@@]1(C[C@@H]([C@]3([C@H]2CCC4=CC(=O)C=C[C@@]43C)F)O)C)C)C(=O)CCl
InChI
InChI=1S/C25H32ClFO5/c1-5-21(31)32-25(20(30)13-26)14(2)10-18-17-7-6-15-11-16(28)8-9-22(15,3)24(17,27)19(29)12-23(18,25)4/h8-9,11,14,17-19,29H,5-7,10,12-13H2,1-4H3/t14-,17-,18-,19-,22-,23-,24-,25-/m0/s1
InChIKey
CBGUOGMQLZIXBE-XGQKBEPLSA-N
Cross-matching ID
PubChem CID
32798
ChEBI ID
CHEBI:31414
CAS Number
25122-46-7
UNII
779619577M
DrugBank ID
DB01013
TTD ID
D0H0YD
INTEDE ID
DR0344
ACDINA ID
D00954
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Gene/Protein Processing [7]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Gene/Protein Processing [8]
Glutamate--cysteine ligase catalytic subunit (GCLC) OTESDI4D GSH1_HUMAN Gene/Protein Processing [8]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Gene/Protein Processing [8]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Gene/Protein Processing [9]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Cetyl alcohol E00061 2682 Coating agent; Emollient; Emulsifying agent; Stiffening agent
Kyselina citronova E00014 311 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Potassium citrate E00225 13344 Alkalizing agent; Buffering agent; Complexing agent
Propylene glycol E00040 1030 Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Stearyl alcohol E00172 8221 Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Water E00035 962 Solvent
Butane E00155 7843 Aerosol propellant
Propane E00115 6334 Aerosol propellant
Polysorbate 60 E00715 Not Available Dispersing agent; Emollient; Emulsifying agent; Surfactant; Plasticizing agent; Solubilizing agent; Suspending agent
⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Clobetasol Propionate 0.05% aerosol 0.05% Aerosol Inhalation
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Post-traumatic erosive dermatosis of the scalp: A?hypergranulated variant. Australas J Dermatol. 2019 Nov;60(4):e322-e326.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 FDA Approved Drug Products: Olux-E Clobetasol Propionate Topical Aerosol Foam
4 Urichuk L, Prior TI, Dursun S, Baker G: Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 Jun;9(5):410-8.
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Cytochrome p450: a target for drug development for skin diseases. J Invest Dermatol. 2004 Sep;123(3):417-25.
7 Retinoic acid antagonizes basal as well as coal tar and glucocorticoid-induced cytochrome P4501A1 expression in human skin. Carcinogenesis. 1995 Mar;16(3):519-24.
8 Regulation of cutaneous drug-metabolizing enzymes and cytoprotective gene expression by topical drugs in human skin in vivo. Br J Dermatol. 2006 Aug;155(2):275-81.
9 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.